Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 93 clinical trials
Pancreatic Ductal Adenocarcinoma - Microbiome as Predictor of Subtypes

and tumoral microbiome in PDAC patients and associate findings with genetic, transcriptional and clinical data, in particular with treatment response.

breast ductal carcinoma
pancreatic ductal adenocarcinoma
pdac
adenocarcinoma
  • 0 views
  • 19 Jun, 2021
  • 2 locations
  • 0 views
  • 09 Sep, 2023
  • 8 locations
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before

ductal adenocarcinoma
pancreatic adenocarcinoma
breast ductal carcinoma
leucovorin
oxaliplatin
  • 10 views
  • 15 Jun, 2022
  • 1 location
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical Trial

This study is designed to explore the efficacy and safety of surufatinib combined with camrelizumab and AS (nab-paclitaxel and S-1) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in unresectable advanced or metastatic pancreatic cancer.

platelet count
paclitaxel
gemcitabine
neutrophil count
metastatic pancreatic cancer
  • 0 views
  • 12 Oct, 2022
  • 1 location
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer

Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic MSS CRC who have exposure to 2 or more lines

nivolumab
oxaliplatin
cancer chemotherapy
KRAS
immunostimulant
  • 5 views
  • 10 Sep, 2023
  • 1 location
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (SEPION)

pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients with

azacitidine
ductal adenocarcinoma
measurable disease
paclitaxel
lenalidomide
  • 1 views
  • 23 May, 2022
  • 9 locations
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

(r/r) glioblastoma multiforme (GBM), breast cancer (BC) that has metastasized to the brain, gastroesophageal adenocarcinoma (GEA) or pancreatic ductal adenocarcinoma (PDAC) expected to overexpress

cancer
HER2
EGFR
bevacizumab
  • 0 views
  • 06 Apr, 2023
  • 2 locations
Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial (APACaPOp)

study aims to explore the effects of adapted physical activity (APA) in patients with resected pancreatic ductal adenocarcinoma (PDAC).

breast ductal carcinoma
pancreatic ductal adenocarcinoma
cancer chemotherapy
metastasis
immunostimulant
  • 17 views
  • 01 Feb, 2022
  • 3 locations
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

-paclitaxel in participants with pancreatic ductal adenocarcinoma (PDAC) .

estrogen
estrogen receptor
metastatic breast cancer
paclitaxel
gemcitabine
  • 0 views
  • 07 Oct, 2022
  • 13 locations
LAPTOP: Phase 1/2 Study in Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer to Assess Safety and Potential Efficacy of Dual Checkpoint Inhibition in Combination With Gemcitabine and Nab-paclitaxel Followed by Immune-chemoradiation. (LAPTOP)

Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally

  • 0 views
  • 21 Oct, 2022
  • 1 location